Y-mAbs Therapeutics (NASDAQ:YMAB) & Gemini Therapeutics (NASDAQ:GMTX) Head-To-Head Contrast

Y-mAbs Therapeutics (NASDAQ:YMAB) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares Y-mAbs Therapeutics and Gemini Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	-28.22%	-24.61%	-18.49%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Earnings and Valuation

This table compares Y-mAbs Therapeutics and Gemini Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	$84.55 million	4.32	-$21.43 million	($0.54)	-15.09
Gemini Therapeutics	N/A	N/A	-$71.87 million	($1.00)	-65.01

Y-mAbs Therapeutics has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Y-mAbs Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Y-mAbs Therapeutics and Gemini Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	1	0	7	2	3.00
Gemini Therapeutics	0	0	0	0	0.00

Y-mAbs Therapeutics presently has a consensus target price of $20.89, suggesting a potential upside of 156.31%. Given Y-mAbs Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than Gemini Therapeutics.

Insider and Institutional Ownership

70.8% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 22.5% of Y-mAbs Therapeutics shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Y-mAbs Therapeutics beats Gemini Therapeutics on 12 of the 14 factors compared between the two stocks.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

About Gemini Therapeutics

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.